Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naive ALK-positive NSCLC patients

被引：0
|
作者：
不详
机构：
来源：
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2016年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [1] Ensartinib vs crizotinib in ALK-positive NSCLC
    Venkatesan, Priya
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [2] Brigatinib versus crizotinib for ALK-positive NSCLC
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (11): : E585 - E585
  • [3] Brigatinib (Alunbrig®) - New Option for Crizotinib-pretreated adult Patients with ALK-positive non-small cell Lung Carcinoma (ALK plus NSCLC)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (1-2) : 74 - 74
  • [4] Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
    Gainor, Justin F.
    Tan, Daniel S. W.
    De Pas, Tomasso
    Solomon, Benjamin J.
    Ahmad, Aziah
    Lazzari, Chiara
    de Marinis, Filippo
    Spitaleri, Gianluca
    Schultz, Katherine
    Friboulet, Luc
    Yeap, Beow Y.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2745 - 2752
  • [5] EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
    Asao, T.
    Honma, Y.
    Suina, K.
    Muraki, K.
    Shukuya, T.
    Ohashi, R.
    Koyama, R.
    Shimada, N.
    Sakuraba, S.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [6] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [7] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [8] Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
    Camidge, D. Ross
    Kim, Elizabeth E.
    Usari, Tiziana
    Polli, Anna
    Lewis, Iona
    Wilner, Keith D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1077 - 1085
  • [9] Ceritinib Alone for Crizotinib-naive Versus Crizotinib-pretreated for Management of Anaplastic Lymphoma Kinase-rearrangement Non-Small-cell Lung Cancer: ASystematic Review
    Zhao, Xuewei
    Feng, Zhangying
    Wang, Guanqi
    Pang, Haiying
    Wang, Mingxia
    CLINICAL LUNG CANCER, 2018, 19 (06) : E945 - E956
  • [10] A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naive and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC)
    Gainor, Justin F.
    Varghese, Anna M.
    Ou, Sai-Hong Ignatius
    Kabraji, Sheheryar
    Awad, Mark M.
    Katayama, Ryohei
    Pawlak, Amanda
    Mino-Kenudson, Mari
    Yeap, Beow Y.
    Riely, Gregory J.
    Iafrate, Anthony John
    Arcila, Maria E.
    Ladanyi, Marc
    Engelman, Jeffrey A.
    Dias-Santagata, Dora
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345